It looks like you're using an Ad Blocker.
Please white-list or disable AboveTopSecret.com in your ad-blocking tool.
Thank you.
Some features of ATS will be disabled while you continue to use an ad-blocker.
Molnupiravir active metabolite (NHC-5’ Triphosphate), acts as a competitive alternative substrate for viral RNA
causing viral mutagenesis or mutations, which leads to viral error catastrophe and extinction of replication
There is some concern about the safety of NHC -nucleoside triphosphate, which is also mutagenic to mammalian cells
Of course, Molnupiravir also causes mutations in human DNA [2] [6], but those consequences (cancer, birth defects etc.) will only present themselves later, and their connection to the drug will be denied. Only one study of Molnupiravir’s side effects had been conducted [7] [8].
Additionally, Molnupiravir does not stop coronavirus replication immediately. Multiple replication cycles take place within each host under Molnupiravir. The unfit genomes are eliminated, and the fitter ones (immune escape, higher infectivity etc.) are preferred. This further increases the chances of a large mutation set increasing the virus’ fitness.
Looking up molnupiravir in the mainstream press you’ll notice that none of them refer to this drug as a “mutagen”, but instead as an RNA polymerase target. This may seem like a game of semantics, but the notion that a drug can act as a possible mutagen, and therefore a carcinogen, and is not being discussed in the mainstream means that millions of Americans may be left uninformed about these possible side effects, and may possibly put themselves at harms risk if they are prescribed this drug.
originally posted by: DontTreadOnMe
This sounds INSANE to me!
Does that mean that those who got very little effect from the jabs are barely safe? That those immune systems are weak?
An antibody treatment developed by pharmaceutical giant AstraZeneca has shown its ability to both prevent and treat Covid-19, according to new data.
AstraZeneca submitted a request to the US Food and Drug Administration (FDA) last week for emergency use authorisation for AZD7442, which is made up of two antibodies, as a preventative treatment.